Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination

類似資料

• Therapeutic effectiveness of intratumorally-delivered dendritic cells engineered to express the pro-inflammatory cytokine, interleukin (IL)-32
  著者:: Qu, Yanyan, 等
  出版事項: (2011)
• Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma
  著者:: Lowe, Devin B, 等
  出版事項: (2014)
• MDSC as a Mechanism of Tumor Escape from Sunitinib Mediated Anti-Angiogenic Therapy
  著者:: Finke, James, 等
  出版事項: (2011)
• Combined vaccine + axitinib therapy yields superior anti-tumor efficacy in a murine melanoma model
  著者:: Bose, Anamika, 等
  出版事項: (2012)
• Direct and Differential Suppression of Myeloid-derived Suppressor Cell Subsets by Sunitinib is Compartmentally Constrained
  著者:: Ko, Jennifer S, 等
  出版事項: (2010)